Pluri Inc. (NASDAQ:PLUR) Short Interest Update

Pluri Inc. (NASDAQ:PLUR) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 35,400 shares, a growth of 176.6% from the March 31st total of 12,800 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily volume of 29,700 shares, the days-to-cover ratio is presently 1.2 days.

Pluri Trading Up 9.4 %

PLUR stock traded up $0.46 during midday trading on Friday, reaching $5.36. 6,867 shares of the company traded hands, compared to its average volume of 24,991. The firm has a market capitalization of $27.76 million, a price-to-earnings ratio of -1.16 and a beta of 1.45. The company has a debt-to-equity ratio of 3.69, a quick ratio of 7.12 and a current ratio of 7.12. The business has a 50 day moving average of $6.42 and a 200-day moving average of $5.33. Pluri has a 52-week low of $3.45 and a 52-week high of $8.56.

Pluri (NASDAQ:PLUR) last released its quarterly earnings results on Monday, February 12th. The company reported ($0.96) EPS for the quarter. The firm had revenue of $0.11 million for the quarter. Pluri had a negative return on equity of 177.94% and a negative net margin of 6,708.40%.

Hedge Funds Weigh In On Pluri

A hedge fund recently raised its stake in Pluri stock. Values First Advisors Inc. raised its holdings in shares of Pluri Inc. (NASDAQ:PLUR) by 168.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 135,547 shares of the company’s stock after purchasing an additional 85,037 shares during the period. Values First Advisors Inc. owned 0.33% of Pluri worth $81,000 at the end of the most recent quarter. Institutional investors own 16.59% of the company’s stock.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.